Thermo Fisher Scientific Inc. (TMO)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for TMO is $667.12, 3.3% below the last close of $690.00 on Oct 16, 2026; targets range from $527.07 to $765.60. Rating consensus: Buy.
Snapshot
- P/E37.1x
- P/E vs sector+31.8%
- P/E vs own+31.3%
- Target upside-3.3%
- ConsensusBuy
- Market cap$255B
- FCF yield+2.9%
- Insiders-$61.56M
- Earnings in5d
- News
Why it moved
Thermo Fisher Scientific Inc. (TMO) fell 0.9% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
2 stories on the day (30-day average 0.9).
- Banque Pictet & Cie SA Sells 6,618 Shares of Thermo Fisher Scientific Inc. $TMO
- What Analyst Projections for Key Metrics Reveal About Thermo Fisher (TMO) Q3 Earnings
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $690.00 · +29.0% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50—
- RSI64
- Support-8.7%
- Resistance—
- Off 52w high-0.9%
- Off ATH-0.9%
- 52w range$690.00
- Bollingerupper half
- MACD0.46
- ATR+2.7%
- Volume1.0x
Analyst price targets
19 firms with a target in the last 12 months · last close $690.00 · as of Oct 16, 2026
Strong buy 4 · Buy 20 · Hold 4 · Sell 0 · Strong sell 1
Revenue and free cash flow
Q2 FY2026: Revenue +10.5% year over year, free cash flow 14.0% of revenue, operating margin 17.4%.
| Q2 FY2026 | Jun 27, 2026 | $11.99B | 4.68 | $1.68B | 41.2% | 17.4% | 14.5% |
| Q1 FY2026 | Mar 28, 2026 | $11.01B | 4.43 | $816M | 40.7% | 16.9% | 15.0% |
| Q4 FY2025 | Dec 31, 2025 | $12.21B | 5.21 | $2.99B | 41.0% | 18.8% | 16.2% |
| Q3 FY2025 | Sep 27, 2025 | $11.12B | 4.27 | $1.83B | 41.2% | 18.7% | 14.5% |
| Q2 FY2025 | Jun 28, 2025 | $10.85B | 4.28 | $1.1B | 40.6% | 17.7% | 14.9% |
| Q1 FY2025 | Mar 29, 2025 | $10.36B | 3.98 | $361M | 41.0% | 17.8% | 14.5% |
| Q4 FY2024 | Dec 31, 2024 | $11.39B | 4.78 | $2.81B | 39.2% | 19.9% | 16.1% |
| Q3 FY2024 | Sep 28, 2024 | $10.6B | 4.24 | $1.89B | 41.0% | 18.1% | 15.4% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 | | $690.00 | -0.9% | -0.9% | -3.3% | 37.1 | $255B | |
| 2 |  | $229.04 | -1.1% | -4.8% | +2.8% | 40.7 | $161B | |
| 3 |  | $172.97 | -1.5% | -1.5% | +0.5% | 34.0 | $48.77B | |
| 4 |  | $560.36 | +2.4% | -26.9% | +34.9% | 39.7 | $44.15B | |
| 5 |  | $266.90 | -1.5% | -3.0% | +3.6% | 33.1 | $43.93B | |
| 6 |  | $436.95 | -1.6% | -1.6% | +4.4% | 109.0 | $42.9B | |
| 7 |  | $262.54 | -2.0% | -10.6% | -16.6% | 49.0 | $39.64B | |
| 8 |  | $1,622.29 | -1.0% | -1.0% | -7.3% | 36.5 | $32.51B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.